In a phase 1 dose-escalation study, treatment with revumenib (SNDX-5613) within a heavily pre-treated (median of 4 prior therapies) population of 68 patients with predominantly KMT2A-rearranged or NPM1-mutated leukemia resulted in a composite CR (CR/CRh/CRp) rate of 38% (N = 23), with slightly higher rates of CR/CRh observed in patients with KMT2A-rearranged (33%, N = 15/46) versus NPM1-mutated AML (21%, N = 3/14). The gene discussed is NPM1; the disease is leukemia.